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Introduction: Hypersensitivity pneumonitis is a complex syndrome resulting from repeated 
inhalation and sensitisation to a variety of antigenic stimuli. The majority of cases are classified as 
chronic and may result in fibrotic progression which can be hard to distinguish from that of 
idiopathic pulmonary fibrosis (IPF). Precise aetiology and optimal management strategies are less 
well defined than for IPF, although clinical trials exploring the use of pirfenidone (NCT02496182) and 
nintedanib (NCT02999178) are in progress. 
Objectives: To establish a large, UK-based, multicentre, retrospective cohort of patients with cHP to 
facilitate detailed investigation of patient demographics, management and prognosis.  
Methods: We performed a multicentre evaluation of clinical data for patients who presented to the 
interstitial lung disease clinics at the North Bristol NHS Trust, University Hospitals of Leicester NHS 
Trust, Taunton and Somerset NHS Foundation Trust and the Royal Devon & Exeter NHS Foundation 
Trust and who required multidisciplinary team evaluation between 2005 and 2018. Basic 
demographics and survival were compared using chi-square test with Yates correction (gender), 
Mann-Whitney U-test (age at presentation) and Kaplan-Meier Survival analysis in Graphpad Prism. 
Results: In total, 397 patients with a diagnosis of cHP were identified, compared with 1068 patients 
with IPF. There was a significant difference in age at diagnosis between cHP and IPF (median 72.0 vs 
75.6, p<0.0001), and a highly significant difference in gender distribution, with a greater proportion 
of women presenting with cHP than men (237 female vs 160 male, p<0.001), in stark contrast to 
cases of IPF (246 female vs 822 male). cHP is associated with a better prognosis than IPF (p<0.05), 
with a median survival of 7.1 years following diagnosis compared with 3.0 years for IPF. 
Conclusions: Despite challenges in diagnosing cHP (as demonstrated by Walsh et al1 in their review 
of UK MDT agreement where HP has a fair kappa score of 0.29) and in line with published literature, 
our cHP cohort has a female preponderance and is associated with better survival than IPF. This 
cohort will provide a crucial resource for more detailed analysis of patient data (e.g. spirometry and 
response to therapy). 
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